“ Over the last two years, the Czech Republic has achieved big advances in terms of patient advocacy, and we should influence other CEE countries in this… ”
In Conversation
“ To survive in Hungary we do not bring me-too products to market but instead, work to fill the gaps which exist ”
“ Our cumulative sales of biosimilars have reached EUR 140 million, and we are the market leader for infliximab, rituximab and trastuzumab biosimilar in the region. ”
“ While the level of generic penetration is still the same — it has barely changed in proportion to innovators— the price pressure, especially in generics, comes… ”
“ Pharma companies in the Czech Republic grow by double-digits every year. At first, they encounter many difficulties to access the market, but once they achieve that,… ”
“ It is important to have smart investors, willing to take a higher risk, who value factors such as know-how and Intellectual Property, and who are relatively… ”
“ Many people in the industry were worried about what would happen if all phase I studies disappeared from Sweden, and in retrospect, I have realized how… ”
“ Although the Czech Medical Association in its current form dates back to a 1992 statute, our oldest journal was published as far back as 1862 ”
“ [Hungarian] patients are suspicious of prescribed medicine and tend to prefer homoeopathic or natural alternatives ”
“ Just like we had a mission for chemical generics, our future focus will be to build awareness and educate society on biosimilars and the unique value… ”
Mátyás Szentiványi – Director General, National Institute of Pharmacy and Nutrition (OGYEI), Hungary
“ While there is a mixed view amongst Hungarians about healthcare in the country, all stakeholders have been making conscious efforts for enhancement, and as a Hungarian,… ”
“ Hungary is a good position as it has the luxury to observe the best practices of the first adopters such as the United States and Europe. ”
